Primary central nervous system lymphoma.
CNS lymphoma
High-dose methotrexate
Neuro-oncology
Whole brain radiotherapy
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
received:
05
11
2023
accepted:
30
11
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma (NHL) manifesting in the brain, spinal cord, cerebrospinal fluid and/or eyes, in the absence of systemic manifestations. With an increasing incidence and a 30% 5-year overall survival if promptly treated, timely diagnosis and subsequent treatment is paramount. The typical MRI appearance for PCNSL is a solitary or multiple T2-hypointense, homogeneous gadolinium-enhancing lesion with restricted diffusion. Dexamethasone treatment might compromise and delay the diagnosis. Hallmark of treatment is induction with intravenous high-dose methotrexate consisting polychemotherapy followed by consolidation treatment. Consolidation treatment consists of either whole brain radiotherapy (WBRT) or autologous stem cell transplantation (ASCT). Given the (cognitive) side effects of WBRT, ASCT is increasingly being used as the first choice of treatment.
Identifiants
pubmed: 38112784
doi: 10.1007/s00415-023-12143-w
pii: 10.1007/s00415-023-12143-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
O’Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 88:997–1000. https://doi.org/10.1002/AJH.23551
doi: 10.1002/AJH.23551
pubmed: 23873804
pmcid: 4020348
Mendez JS, Ostrom QT, Gittleman H et al (2018) The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 20:687–694. https://doi.org/10.1093/NEUONC/NOX187
doi: 10.1093/NEUONC/NOX187
pubmed: 29036697
Touitou V, Lehoang P, Bodaghi B (2015) Primary CNS lymphoma. Curr Opin Ophthalmol 26:526–533. https://doi.org/10.1097/ICU.0000000000000213
doi: 10.1097/ICU.0000000000000213
pubmed: 26367092
Bataille B, Delwail V, Menet E et al (2000) Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92:261–266. https://doi.org/10.3171/jns.2000.92.2.0261
doi: 10.3171/jns.2000.92.2.0261
pubmed: 10659013
Küker W, Nägele T, Korfel A et al (2005) Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72:169–177. https://doi.org/10.1007/S11060-004-3390-7
doi: 10.1007/S11060-004-3390-7
pubmed: 15925998
Tabouret E, Houillier C, Martin-Duverneuil N et al (2017) Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: Imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro Oncol 19:422–429. https://doi.org/10.1093/neuonc/now238
doi: 10.1093/neuonc/now238
pubmed: 27994065
Mohile NA, Deangelis LM, Abrey LE (2008) The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. https://doi.org/10.1215/15228517-2007-061
doi: 10.1215/15228517-2007-061
pubmed: 18287338
pmcid: 2613825
Malani R, Bhatia A, Wolfe J, Grommes C (2019) Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions. Leuk Lymphoma. https://doi.org/10.1080/10428194.2018.1563294
doi: 10.1080/10428194.2018.1563294
pubmed: 30628502
pmcid: 6620158
Barajas RF, Politi LS, Anzalone N et al (2021) Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the international primary CNS lymphoma collaborative group (IPCG). Neuro Oncol. https://doi.org/10.1093/neuonc/noab020
doi: 10.1093/neuonc/noab020
pubmed: 33560416
pmcid: 8248856
Makino K, Hirai T, Nakamura H et al (2011) Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Ann Nucl Med. https://doi.org/10.1007/s12149-011-0483-1
doi: 10.1007/s12149-011-0483-1
pubmed: 21404136
Rozenblum L, Houillier C, Soussain C et al (2022) Role of positron emission tomography in primary central nervous system lymphoma. Cancers (Basel). https://doi.org/10.3390/cancers14174071
doi: 10.3390/cancers14174071
pubmed: 36077613
Alaggio R, Amador C, Anagnostopoulos I et al (2023) Correction: “The 5th edition of The World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms”. Leukemia. 2022 Jul;36(7):1720–1748. Leukemia 37:1944–1951. https://doi.org/10.1038/s41375-023-01962-5
Brück W, Brunn A, Klapper W et al (2013) Differential diagnosis of lymphoid infiltrates in the central nervous system: experience of the network lymphomas and lymphomatoid lesions in the nervous system. Pathologe 34:186–197. https://doi.org/10.1007/S00292-013-1742-9
doi: 10.1007/S00292-013-1742-9
pubmed: 23471726
Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability—PubMed. https://pubmed.ncbi.nlm.nih.gov/26339344/ . Accessed 26 Oct 2023
Saggese CE, Cecotti L, Lazzarino De Lorenzo LG (2013) Neuroborreliosis and CNS lymphoma: what is the nexus? Neurol Sci 34:2253–2254. https://doi.org/10.1007/s10072-013-1492-8
doi: 10.1007/s10072-013-1492-8
pubmed: 23934519
Bromberg JEC, Breems DA, Kraan J et al (2007) CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 68:1674–1679. https://doi.org/10.1212/01.WNL.0000261909.28915.83
doi: 10.1212/01.WNL.0000261909.28915.83
pubmed: 17502548
Morell AA, Shah AH, Cavallo C et al (2019) Diagnosis of primary central nervous system lymphoma: a systematic review of the utility of CSF screening and the role of early brain biopsy. Neurooncol Pract 6:415–423. https://doi.org/10.1093/nop/npz015
doi: 10.1093/nop/npz015
pubmed: 31832211
pmcid: 6899047
Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ et al (2019) MYD88 p. (L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma. Br J Haematol 185:974–977. https://doi.org/10.1111/BJH.15674
doi: 10.1111/BJH.15674
pubmed: 30408153
Cassoux N, Merle-Beral H, Leblond V et al (2000) Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 8:243–250. https://doi.org/10.1076/OCII.8.4.243.6463
doi: 10.1076/OCII.8.4.243.6463
pubmed: 11262654
Hoang-Xuan K, Deckert M, Ferreri AJM et al (2023) European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol 25:37–53. https://doi.org/10.1093/neuonc/noac196
doi: 10.1093/neuonc/noac196
pubmed: 35953526
Grimm SA, Pulido JS, Jahnke K et al (2007) Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report. Ann Oncol 18:1851–1855. https://doi.org/10.1093/ANNONC/MDM340
doi: 10.1093/ANNONC/MDM340
pubmed: 17804469
Ferreri AJM, Cwynarski K, Pulczynski E et al (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol 4:e510–e523. https://doi.org/10.1016/S2352-3026(17)30174-6
doi: 10.1016/S2352-3026(17)30174-6
pubmed: 29054815
Bromberg JEC, Issa S, Bakunina K et al (2019) Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 20:216–228. https://doi.org/10.1016/S1470-2045(18)30747-2
doi: 10.1016/S1470-2045(18)30747-2
pubmed: 30630772
Doolittle ND, Korfel A, Lubow MA et al (2013) Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 81:84–92. https://doi.org/10.1212/WNL.0B013E318297EEBA
doi: 10.1212/WNL.0B013E318297EEBA
pubmed: 23685932
pmcid: 3770201
Correa DD, Braun E, Kryza-Lacombe M et al (2019) Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. J Neurooncol 144:553–562. https://doi.org/10.1007/s11060-019-03257-1
doi: 10.1007/s11060-019-03257-1
pubmed: 31377920
pmcid: 7392129
Scordo M, Wang TP, Ahn KW et al (2021) Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol 7:993–1003. https://doi.org/10.1001/JAMAONCOL.2021.1074
doi: 10.1001/JAMAONCOL.2021.1074
pubmed: 33956047
pmcid: 8283558
Alnahhas I, Jawish M, Alsawas M et al (2019) Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 19:e129–e141. https://doi.org/10.1016/J.CLML.2018.11.018
doi: 10.1016/J.CLML.2018.11.018
pubmed: 30584023
Soussain C, Choquet S, Fourme E et al (2012) Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 97:1751–1756. https://doi.org/10.3324/haematol.2011.060434
doi: 10.3324/haematol.2011.060434
pubmed: 22581000
pmcid: 3487451
Houillier C, Taillandier L, Dureau S et al (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823–833. https://doi.org/10.1200/JCO.18.00306
doi: 10.1200/JCO.18.00306
pubmed: 30785830
de Faber S, Mutsaers P, van den Bent M, van der Meulen M (2021) Subacute neurological deficits and respiratory insufficiency due to intrathecal methotrexate. J Clin Transl Res. https://doi.org/10.18053/jctres.07.202106.013
doi: 10.18053/jctres.07.202106.013
pubmed: 34988333
pmcid: 8717579
Kasenda B, Ferreri AJM, Marturano E et al (2015) First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Ann Oncol 26:1305–1313. https://doi.org/10.1093/ANNONC/MDV076
doi: 10.1093/ANNONC/MDV076
pubmed: 25701456
pmcid: 4735103
Fritsch K, Kasenda B, Schorb E et al (2017) High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 31:846–852. https://doi.org/10.1038/LEU.2016.334
doi: 10.1038/LEU.2016.334
pubmed: 27843136
Abrey LE, Batchelor TT, Ferreri AJM et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043. https://doi.org/10.1200/JCO.2005.13.524
doi: 10.1200/JCO.2005.13.524
pubmed: 15955902
van der Meulen M, Postma AA, Smits M et al (2021) Extent of radiological response does not reflect survival in primary central nervous system lymphoma. Neurooncol Adv 3:vda007. https://doi.org/10.1093/noajnl/vdab007
doi: 10.1093/noajnl/vdab007
Van Der Meulen M, Dinmohamed AG, Visser O et al (2017) Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015. Leukemia 31:1822–1825. https://doi.org/10.1038/leu.2017.128
doi: 10.1038/leu.2017.128
pubmed: 28450731
Ferreri AJM, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 21:266–272. https://doi.org/10.1200/JCO.2003.09.139
doi: 10.1200/JCO.2003.09.139
pubmed: 12525518
van der Meulen M, Dirven L, Bakunina K et al (2021) MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma. J Neurooncol 152:357–362. https://doi.org/10.1007/s11060-021-03708-8
doi: 10.1007/s11060-021-03708-8
pubmed: 33611761
pmcid: 7997829